

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA ISOTOPE & RADIATION CORPORATION

中國同輻股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1763)

INSIDE INFORMATION

PROPOSED GRATUITOUS TRANSFER OF EQUITY INTERESTS BY CONTROLLING SHAREHOLDER

WAIVER FROM MANDATORY GENERAL OFFER REQUIREMENT

This announcement is made by China Isotope & Radiation Corporation (the “**Company**”) pursuant to Rule 13.09 of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Company has been informed by China National Nuclear Corporation (中國核工業集團有限公司) (“**CNNC**”, together with its subsidiaries, “**CNNC Group**”), its controlling shareholder, that as part of an intra-group restructuring, it is proposed that CNNC will gratuitously transfer all of the 106,676,903 domestic shares in the Company held by it (the “**Relevant Shares**”), representing approximately 33.35% of the Company’s total issued share capital as of the date of this announcement (the “**Proposed Gratuitous Transfer**”), to China Baoyuan Investment Co., Ltd. (中國寶原投資有限公司) (the “**Transferee**”). Both the Transferee and the Company are under the control of and are, respectively, subsidiaries directly and indirectly held by CNNC.

The Transferee is a wholly-owned subsidiary of CNNC. Established in the PRC with limited liability, the Transferee specialises in implementing CNNC’s medium and long-term development strategy for its nuclear technology application business, forging an industry chain that covers most aspects of nuclear technology application, from technology, products to service applications. The Transferee cemented its lead in the nuclear technology industry and in medical applications through its integration of research and development, production, sales, and services. The Transferee has been a shareholder of the Company since its listing on the main board of the Stock Exchange in 2018, holding equity interests (domestic shares) of approximately 0.44% of the Company’s total issued share capital as of the date of this announcement.

Upon completion of the Proposed Gratuitous Transfer, the Transferee will become the direct controlling shareholder of the Company, while CNNC will remain the Company's ultimate controlling shareholder.

The Transferee has applied for, and the Securities and Futures Commission of Hong Kong has granted a waiver pursuant to Note 6(a) to Rule 26.1 of the Code on Takeovers and Mergers (the **"Takeovers Code"**) (on the basis that each of CNNC and the Transferee is within the same group of companies (i.e. the CNNC Group) comprising the parent company and its subsidiaries) waiving the obligation on the part of the Transferee to make a mandatory general offer that would otherwise be triggered by the Proposed Gratuitous Transfer of the Relevant Shares to the Transferee under Rule 26.1(a) of the Takeovers Code. **Accordingly, the Proposed Gratuitous Transfer of the Relevant Shares to the Transferee will not give rise to any obligation on the Transferee to make a mandatory general offer for shares of the Company.**

The directors of the Company noted that the Proposed Gratuitous Transfer is still at a preliminary stage and it is still uncertain as to whether the Proposed Gratuitous Transfer will materialise. The Company will make further announcement(s) on the Proposed Gratuitous Transfer as and when appropriate in accordance with the Listing Rules and fulfill its information disclosure obligations in a timely manner in accordance with the relevant laws and regulations.

Shareholders and the public are reminded to exercise caution when dealing in the securities of the Company.

By order of the Board
China Isotope & Radiation Corporation
Wang Suohui
Chairman

Beijing, the PRC, 15 September 2023

As at the date of this announcement, the Board comprises Mr. Wang Suohui, Mr. Xu Hongchao and Mr. Du Jin as executive Directors; Mr. Chen Shoulei, Mr. Ding Jianmin, Ms. Chang Jinyu and Ms. Liu Xiuhong as non-executive Directors; and Mr. Poon Chiu Kwok, Mr. Tian Jiahe, Ms. Chen Jingshan and Mr. Lu Chuang as independent non-executive Directors.